West J, Li M, Wong S, Le GH, Teopiz KM, Valentino K, Dri CE, McIntyre RS (2025) Are Glucagon-Like Peptide1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
Thought this was just part of who I am
Higher-likelihood alternative causes: In UK clinical guidance, GSM is a common and under-treated driver of dryness, dyspareunia and tissue fragility, and should be actively assessed, particularly in peri-/post-menopausal patients or those with iatrogenic hypo-oestrogenism
Each medication has different dosing schedules and strengths, but all work similarly in your body and require eye health monitoring
This is why oral formulations are such a focus area for the leaders in the pack, Novo and Lilly, as well as newer entrants like Kailera, Metsera, and Verdiva
Do not double-dose